Understanding PCDHGC3: A Rare Genetic Disorder (G5098)

Target Name: PCDHGC3

NCBI ID: G5098

PCDHGC3

Understanding PCDHGC3: A Rare Genetic Disorder

PCDHGC3 (Peripheral Capillary Dysplasia with Intracranial Hypervascularization and Compound) is a rare genetic disorder that is characterized by the development ofcapillaries around theperipherals of the brain, as well as an increased risk of hypervascularization (abnormally increased blood flow) in the intracranial area. This condition is typically diagnosed in childhood and has been found to be associated with a number of negative outcomes, including increased risk of stroke, degeneration, and retinopathy.

Despite the seriousness of PCDHGC3, it is still a relatively rare disorder, with an estimated prevalence of 1 in 100,000 individuals. Additionally, the exact cause of PCDHGC3 is not known, and it is not possible to diagnose the condition without a genetic test.

While the exact cause of PCDHGC3 is not known, it is thought to be caused by a combination of genetic and environmental factors. There is evidence that certain genetic variations, such as those in the PCDHGC3 gene, have been linked to the development of this condition . Additionally, there is evidence that certain environmental factors, such as exposure to certain toxins or radiation, may also play a role in the development of PCDHGC3.

PCDHGC3 is a disorder that is characterized by the development ofcapillaries around theperipherals of the brain, as well as an increased risk of hypervascularization in the intracranial area. This condition is typically diagnosed in childhood and has been found to be associated with a number of negative outcomes , including increased risk of stroke, degeneration, and retinopathy. Despite the seriousness of PCDHGC3, it is still a relatively rare disorder, with an estimated prevalence of 1 in 100,000 individuals. Additionally, the exact cause of PCDHGC3 is not known, and it is not possible to diagnose the condition without a genetic test.

In recent years, researchers have been studying the potential drug targets for PCDHGC3. One potential drug target for this disorder is the protein PCDHGC3 itself. Studies have shown that PCDHGC3 is involved in the development of capillaries and that it may be a useful target for drugs that can be used to treat this condition.

Another potential drug target for PCDHGC3 is the molecule that is produced by the PCDHGC3 gene. This molecule, called PCDHGC3, has been shown to be involved in the development of capillaries and may be a useful target for drugs that can be used to treat this condition.

In addition to these potential drug targets, researchers are also studying the potential uses of other molecules that may be involved in the development and progression of PCDHGC3. These molecules include growth factors, signaling molecules, and cytokines.

While the exact cause of PCDHGC3 is not known, it is thought to be caused by a combination of genetic and environmental factors. There is evidence that certain genetic variations, such as those in the PCDHGC3 gene, have been linked to the development of this condition . Additionally, there is evidence that certain environmental factors, such as exposure to certain toxins or radiation, may also play a role in the development of PCDHGC3.

In conclusion, PCDHGC3 is a rare genetic disorder that is characterized by the development of capillaries around the peripheral areas of the brain and an increased risk of hypervascularization in the intracranial area. While the exact cause of PCDHGC3 is not known, it is thought to be caused by a combination of genetic and environmental factors. In recent years, researchers have been studying the potential drug targets for PCDHGC3, including the protein PCDHGC3 itself and the molecule

Protein Name: Protocadherin Gamma Subfamily C, 3

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHGC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHGC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets